Dr. Y. K. Hamied
Dr Y.K. Hamied is Non-Executive Chairman of the Company, and represents the second generation of Cipla’s founding family. A world-renowned scientist, Dr Hamied obtained his PhD in organic chemistry in 1960 from the University of Cambridge under the tutelage of the Nobel laureate Lord Alexander Todd.
Dr Y K Hamied is the Non-Executive Chairman of the Company. He represents the second generation of Cipla’s founding family. A world-renowned scientist, Dr Hamied obtained his PhD in Organic Chemistry in 1960 from the University of Cambridge under the tutelage of Nobel Laureate Lord Alexander Todd.
Dr Hamied has been an insightful R&D leader, a courageous industry captain, and an outspoken statesman of global pharma. From affordable drugs in HIV to enabling one of the world’s largest portfolio of drugs and devices in inhalation therapy, his pioneering work and immense contribution to healthcare have been celebrated around the world.
In 2005, Dr Hamied was conferred the Padma Bhushan by the Government of India for his distinguished service to the pharmaceutical industry. In 2013, he was named as one of India’s 25 Greatest Global Living Legends by NDTV, and in 2014, the University of Cambridge honoured him with a DSc the highest honour that the University can bestow. In 2017, Columbia University’s Mailman School of Public Health conferred the ‘Public Health Hero Award’ on Dr Hamied, and in 2018 India Today named him one of ‘20 Global Indians’ who have challenged convention and created history.
Dr Hamied has also been the recipient of several lifetime achievement awards. An Honorary Fellow of the Royal Society of Chemistry, Dr Hamied has frequent presence on high-level international panels on healthcare
Mr. M. K. Hamied
Mr. M. K. Hamied is a science graduate from Bombay University and has vast and varied experience in all functions of the Company including production, technical areas, quality management and general administration.He is Non-Executive Vice-Chairman of the Company and represents the second generation of Cipla’s founding family.
Mr M K Hamied is the Non-Executive Vice-Chairman of the Company and represents the second generation of Cipla’s founding family. A science graduate from Bombay University, Mr Hamied has vast and varied experience in all functions of the Company including production, technical areas, quality management and general administration. He retired as Executive Vice-Chairman of the Company on 31st March, 2014; from 1st April, 2014, he has continued as the Non-Executive Vice-Chairman.
Ms. Samina Hamied
Samina Hamied is an alumna of the London School of Economics. She has worked with the leading global firm Goldman Sachs (UK and US). Samina joined the Cipla leadership team in 2011 as Executive Director, and Global Head – Strategy, Cipla New Ventures.
Samina Hamied is an alumna of the London School of Economics. She has worked with the leading global firm Goldman Sachs (UK & US).
Samina joined the Cipla leadership team in 2011 as Executive Director, and Global Head – Strategy, M&A & Cipla New Ventures. She has been instrumental in driving the Company’s transformation agenda; playing a key role in successfully incubating Cipla’s consumer health business and spearheading the Company’s ambitious foray into the US market with strategic acquisitions. Samina has built a top-class leadership pipeline for the Company as it continues to spread its wings globally.
In her previous role as the Executive Vice-Chairperson of Cipla, Samina focused on board and governance issues, in addition to furthering Cipla’s strategic priorities through key global partnerships, corporate culture, hiring the right talent, and public advocacy. Samina also chaired the Inclusion & Diversity Council at Cipla.
Recognised as the third generation of the founding family, Samina has been feted for her diverse work experience and business knowledge. She was amongst Business Today’s ‘Most Powerful Women in Business’ in 2017 & 2022. In 2018, Forbes featured Samina in the ‘Top 25 Emergent Women Business Leaders in Asia’. Fortune India named her amongst the ‘Most Powerful Women in Business for five consecutive years (2018-2022). She was awarded ‘Businesswoman of the Year’ at The Economic Times Awards for Corporate Excellence in 2021. Most recently, Samina was conferred the ‘EY Entrepreneur of the Year 2022’ in life sciences and healthcare category; and was named among the ‘Most Influential Women in Healthcare 2023’ by BW Healthcare World.
Mr. Umang Vohra
Umang Vohra is Managing Director and Global Chief Executive Officer (MD and GCEO) of Cipla since September 2016. Umang joined Cipla in October 2015 as its Global Chief Financial Officer, and from January 2016 to August 2016 was Cipla’s Global Chief Operating Officer.
Mr Umang Vohra joined Cipla Limited in 2015 and has been the MD & GCEO of the Company since September 2016. After gaining degrees in engineering, marketing and finance, Mr Vohra worked with Eicher Motors, PepsiCo and Dr Reddy’s Laboratories. Through his previous roles in India and the US, he has built a distinguished career spanning almost two decades with deep understanding and experience of various aspects of the global pharmaceutical business.
As Cipla’s MD & GCEO, Mr Vohra’s priorities have been Cipla’s strategic growth, defining and executing Cipla’s roadmap to maintain momentum in home markets whilst strengthening its presence in other regions, consolidating its core focus areas, augmenting capability, and building the right organisation. Recognised as an action-oriented industry leader, Mr Vohra is a firm believer in the power of agile business models, disruptive technologies, data-driven analytics and a future-ready workforce with a view to making a difference to the lives of patients.
Mr. Adil Zainulbhai
Mr Adil Zainulbhai is a Mechanical Engineering graduate from the Indian Institute of Technology and an MBA from Harvard Business School. Mr Zainulbhai retired as Chairman of McKinsey, India after a distinguished 34-year career with the firm, including leadership roles in its Washington and Minneapolis offices.
Mr Adil Zainulbhai is a Mechanical Engineering graduate from the Indian Institute of Technology and an MBA from Harvard Business School. Mr Zainulbhai retired as Chairman of McKinsey, India after a distinguished 34-year career with the firm, including leadership roles in its Washington and Minneapolis offices. His influence extends beyond McKinsey, serving as Chairman of the Quality Council of India and as a Board Advisor to the US India Strategic Partnership Forum. He has been a director on the boards of prominent corporates in India like Larsen and Tourbo, Reliance Industries etc. and is the Chairman on the Boards of Network 18 Media and Investments Limited and TV18 Broadcast Limited. He has also been on the international advisory boards of various international organisations and a member of various high powered economic groups, advisory committees and task forces of Government of India.
Mr. P. R. Ramesh
Mr P. R. Ramesh graduated in Commerce from Osmania University, Hyderabad and is a Fellow Member of the ICAI. He retired as the Director of Deloitte & Touche Assurance & Enterprise Risk Services India on 31st March 2020 and has also served as a member of Deloitte Global Board and Deloitte Asia Pacific Board.
Mr P. R. Ramesh graduated in Commerce from Osmania University, Hyderabad and is a Fellow Member of the ICAI. He retired as the Director of Deloitte & Touche Assurance & Enterprise Risk Services India on 31st March 2020 and has also served as a member of Deloitte Global Board and Deloitte Asia Pacific Board. Ramesh has over 40 years of professional experience across manufacturing, banking and financial services, technology, media, telecommunications, energy and resources and consumer business sectors. He has been associated with various Regulatory bodies such as SEBI Committee on Disclosures and Accounting Standards; Committee for Reforming the Regulatory Environment for doing Business in India; Technical Committee to review the form and presentation of the Balance Sheet of the RBI; IRDA Standing Committee on Accounting Issues and Invitee to the Committee set up by the RBI to assist in convergence to IFRS by banks and National Advisory Committee on Accounting Standards. He has been associated with various Industry Bodies such as CII representing on its National Council, Committee on Financial Reporting and its CFO Forum; National Executive Committee of FICCI and Past President of the of the Bombay Chamber of Commerce & Industry. He has also been member of Accounting Standards Board of ICAI, Vision and Restructuring Committee and Auditing Practices Committee of ICAI and the Secretarial Standards Boards of the ICSI. He has co-authored publication by CCH titled iGAAP – Financial Reporting Standards in India including a comparison with IFRS and is a member of Board of Studies and the Faculty of Commerce of Osmania University.
Ms. Punita Lal
Ms Punita Lal is an Independent Non-Executive Director of the Company. She is a B.A. (Hons.) Economics graduate from St. Stephen’s College, Delhi and an MBA from Indian Institute of Management, Kolkata.
Ms Punita Lal is an Independent Non-Executive Director of the Company. She has 30 years of experience in strategy, marketing and leadership in the corporate world across Asia, spanning multiple disciplines, geographies and cultures. Ms Lal has a BA(Hons) in Economics from St Stephen’s College, Delhi and an MBA from the Indian Institute of Management, Kolkata.
As a senior business leader, she has many accolades to her credit, including being chosen as one of India’s top 20 Businesswomen by Business Today in 2006, and being awarded Corporate Woman of the Year in 2009 by the FICCI Women’s Organisation. She is currently practising as an Independent Strategy and Marketing Consultant.
Mr. Robert Stewart
Robert Stewart is an Independent Non-Executive Director of the Company. He has over 34 years of experience in the biopharmaceutical industry having worked with leading companies such as Roche, Abbott, Watson / Actavis / Allergan, Amneal and Theramex. Currently, Robert is the Chief Executive Officer at Theramex Ltd, a global specialty pharmaceutical company.
Robert Stewart is an Independent Non-Executive Director of the Company.
He has over 34 years of experience in the biopharmaceutical industry having worked with leading companies such as Roche, Abbott, Watson / Actavis / Allergan, Amneal and Theramex. Currently, Robert is the Chief Executive Officer at Theramex Ltd, a global specialty pharmaceutical company.
Robert has deep expertise in manufacturing operations, quality, supply chain and general management and a very strong exposure to commercial operations. He has served on the boards of several industry and non-profit organizations and served for nearly two years on the Amneal board of directors.
Robert has a B.S., Business Management from Fairleigh Dickinson University, New Jersey.
Dr. Mandar Vaidya
Dr. Mandar is a medical doctor, and a management graduate from the Jamnalal Bajaj Institute of Management Studies, India.
Dr. Mandar is a medical doctor, and a management graduate from the Jamnalal Bajaj Institute of Management Studies, India.
Mandar spent 15 years at McKinsey (2002-2017), the last seven as partner where he co-led the healthcare practice in India and established the Hospitals practice for Asia. He served leading pharmaceutical companies across India and globally across several areas such as core strategy, manufacturing productivity improvement, R&D productivity, portfolio management, M&A and procurement programs.
From 2017 to 2019 Mandar worked part time advising several healthcare companies, providing leadership coaching and designing and teaching a course on problem solving at Ashoka University.
In Aug 2019, Mandar joined global travel-tech company OYO as CEO – SE Asia & Middle East, driving growth, doubling the number of hotels and homes, while transforming the regions contribution margin to a net positive territory. He led the business through the COVID crisis, improving EBIDTA loss to a negligible level while manging massive business disruptions.
Since March 2021 Mandar is the CEO - OYO Vacation Homes (OVH), Europe, a strategically important core market for the company. OVH is Europe's second largest vacation homes company. Mandar leads three acquired brands, DanCenter, Belvilla and Traum FW, each with a multi decade legacy. He has turbo charged their growth and profitability by migrating them into a tech forward environment while retaining the uniqueness of each businesses bult over the last several decades.
Mandar grew up in Mumbai, but now lives in Gurgaon with his wife and 3-year-old son. He enjoys spending time with his friends, watching movies, and trying out his hand at new pursuits, especially outdoors.
Dr. Balram Bhargava
Dr. Balram Bhargava is a global public health leader. Mission-driven, results-oriented health professional with more than 35 years of experience
Dr. Balram Bhargava is a global public health leader. Mission driven, results oriented health professional with more than 35 years of experience in leading medical research, strengthening health systems, health care innovation, managing pandemic preparedness and health care delivery in resource poor settings. As a global leader he has been in the forefront of south-south cooperation, promoting equity in access to health care, democratisation of scientific research and promoting public-private cooperation to bring new technologies and affordable innovative products into the health systems.
He has led India’s Department of Health Research as its Secretary and Director-General of the Indian Council of Medical Research. He is also a Professor of Cardiology at the All-India Institute of Medical Sciences, New Delhi and serves as the Executive Director for Stanford India Biodesign Centre, School of International Biodesign (SiB). An extensively published scientist with more than 300 articles in peer reviewed journals and editor-in-chief of the British Medical Journal Innovations and of the Indian Journal of Medical Research.
His experience ranges from treating more than a quarter million patients, training and mentoring super specialised cardiologists to setting health care policies and standards and advising several Ministers of Health and Heads of Government. In recent years he has been at the forefront of managing several public health crises in India including covid-19 and brought Indian research in shaping contemporary global practice through vaccine development and describing role of plasma therapy. He has also received numerous international and national awards for his contributions to health and development and has delivered more than 50 orations across the globe. He has international experience of more than 6 years in the USA, Europe and the Middle East.
Sharmila Paranjpe
Sharmila Paranjpe is an Independent Non-Executive Director of the Company. She is an alumnus of COEP Technological University.
Sharmila brings over 30 years of IT industry experience, with more than 25 years spent at Wipro, where she held leadership positions like Country Head for the UK and Global Head of Industrial Manufacturing. She has extensive global expertise in strategy, sales, business development, and program management across various industries. She has successfully led large-scale organizational changes and spearheaded significant business growth and transformation projects.
Sharmila presently also serves as an Executive Director on the Board of Doorstep School Foundation, an NGO focusing on Fundamental Literacy and Numeracy. Sharmila has also shown strong commitment to employee well-being through her roles as Chief Ombudsperson and Chair of the Prevention of Sexual Harassment Committee at Wipro.
Mr. Abhijit Joshi
Mr Abhijit Joshi is the Founding and Managing Partner of a leading law firm M/s Veritas Legal, in India and has over 35 years of experience and expertise in the field of corporate and commercial law, merger & acquisition, risk management, litigation management etc. He is a distinguished dual-qualified solicitor in both India and England.
Mr Abhijit Joshi is the Founding and Managing Partner of a leading law firm M/s Veritas Legal, in India and has over 35 years of experience and expertise in the field of corporate and commercial law, merger & acquisition, risk management, litigation management etc. He is a distinguished dual-qualified solicitor in both India and England. With a legal career spanning over three decades, he is recognized as one of Asia’s Top 15 M&A and Private Wealth Lawyers. Mr Joshi has advised numerous business houses and promoter families, representing global conglomerates and large private equity firms in a wide range of complex deals and cases across various industry sectors, including the pharmaceutical industry. Mr Joshi also possesses skills in global economics, financials, risk management, strategic planning, corporate governance etc. His skills and expertise have earned him several accolades, including the Financial Times Innovation Award (Asia Pacific).